首页> 美国卫生研究院文献>ACS Medicinal Chemistry Letters >Apratoxin S10 a Dual Inhibitor of Angiogenesis andCancer Cell Growth To Treat Highly Vascularized Tumors
【2h】

Apratoxin S10 a Dual Inhibitor of Angiogenesis andCancer Cell Growth To Treat Highly Vascularized Tumors

机译:Apratoxin S10血管生成和血管生成素的双重抑制剂癌细胞生长可治疗高度血管化的肿瘤

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Renal, hepatocellular, and neuroendocrine carcinomas are known as highly vascularized tumors. Although vascular endothelial growth factor A (VEGF-A)-targeted therapies have shown efficacy in the treatment of these cancers, drug resistance is a major concern and might be mediated by interleukin 6 (IL-6). Furthermore, upon antiangiogenic drug exposure, tumor cells may adapt to survive in a vascular-independent manner. Apratoxins are potent marine-derived cytotoxic in vivo-active agents, preventing cotranslational translocation in the secretory pathway, and show promise to overcome resistance by targeting angiogenesis and tumor growth simultaneously. We designed and synthesized a novel apratoxin analogue, apratoxin S10, with a balanced potency and stability as well as synthetic accessibility and scalability. We showed that apratoxin S10 potently inhibits both angiogenesis in vitro and growth of cancer cells from vascularized tumors. Apratoxin S10 down-regulated vascular endothelial growth factor receptor 2 (VEGFR2) on endothelial cells and blocked the secretion of VEGF-A and IL-6 from cancer cells.It inhibited cancer cell growth through down-regulation of multiplereceptor tyrosine kinases (RTKs) and compares favorably to currentlyapproved RTK inhibitors in both angiogenesis and cancer cell growth.
机译:肾癌,肝细胞癌和神经内分泌癌被称为高度血管化的肿瘤。尽管以血管内皮生长因子A(VEGF-A)为靶点的治疗方法已显示出对这些癌症的治疗效果,但耐药性仍是一个主要问题,可能由白介素6(IL-6)介导。此外,在抗血管生成药物暴露后,肿瘤细胞可以适应血管依赖性生存。 Apratoxins是有效的海洋来源的细胞毒性体内活性剂,可防止分泌途径中的共翻译易位,并有望通过同时靶向血管生成和肿瘤生长来克服耐药性。我们设计并合成了一种新型的人毒素毒素类似物,人毒素毒素S10,具有平衡的功效和稳定性以及合成的可及性和可扩展性。我们表明,Apratoxin S10有效地抑制体外血管生成和来自血管瘤的癌细胞的生长。 Apratoxin S10下调了内皮细胞上的血管内皮生长因子受体2(VEGFR2),并阻止了癌细胞分泌VEGF-A和IL-6。它通过下调多种途径抑制癌细胞的生长受体酪氨酸激酶(RTKs),与目前相比是有利的批准的RTK抑制剂可用于血管生成和癌细胞生长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号